Recalls

All US Product Recalls

Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.

How to read this listing

Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means deaths or serious injuries are reported, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.

The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.

Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.

Agency

All agencies FDA (Food)FDA (Drugs)FDA (Devices)USDA FSIS CPSC NHTSA EPA

2976–3000 of 17762

ModerateFDA (Drugs)·D-0350-2023·2023-03-08
DuPont Avicel PH-102 Microcrystalline Cellulose Recalled for Conductivity Specification Failure
DuPont Nutrition USA is recalling Avicel PH-102 NF microcrystalline cellulose excipient due to failed conductivity specifications indicating potential impurities. The product was distributed nationwide and internationally.
Product
Avicel PH- 102 NF, Microcrystalline Cellulose, NF, Ph. Eur., Jp, Net Content/Gross Weight 20.0 KG / 21.1 KG bulk container, Manufactured by: DuPont Nutrition USA, Inc., 1301 Ogletown Road, Newark, DE 19711, USA. Headquarters: DuPont Nutrition Biosciences ApS, Langebrogade 1, Cope
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-0410-2023·2023-03-08
Simvastatin Tablets Recalled Due to Manufacturing Practice Deviations
Accord Healthcare is recalling Simvastatin 20 mg tablets due to manufacturing practice deviations discovered during an FDA inspection. The recall affects 1,394,208 bottles distributed in the United States, Puerto Rico, and Canada.
Product
SIMVASTATIN — SIMVASTATIN (SIMVASTATIN)
Category
Drug
Distribution
1 state
ModerateFDA (Drugs)·D-0404-2023·2023-03-08
Rosuvastatin Tablets 5mg Recalled Due to Manufacturing Practice Deviations
Accord Healthcare is recalling Rosuvastatin tablets 5mg due to manufacturing practice deviations found during an FDA inspection. The recall involves 63,247 bottles distributed across the U.S., Puerto Rico, and Canada.
Product
ROSUVASTATIN — ROSUVASTATIN (ROSUVASTATIN)
Category
Drug
Distribution
1 state
ModerateFDA (Drugs)·D-0413-2023·2023-03-08
Accord Recalls Succinylcholine Chloride Injection Due to Manufacturing Deviations
Accord Healthcare is recalling Succinylcholine Chloride Injection due to manufacturing practice deviations discovered during FDA inspection. The recall affects 48,089 cartons distributed to the U.S., Puerto Rico, and Canada.
Product
Succinylcholine Chloride Injection, USP, 200 mg/10 mL (20 mg/mL), 10 mL Multiple-dose vial in 10x10 carton, Rx Only, Manufactured for: Accord Healthcare, Inc. USA. Manufactured by: Intas Pharmaceuticals Limited, India, Vial NDC 16729-493-03, UPC 3 16729 49303 1; Carton NDC 16729-
Category
Drug
Distribution
1 state
ModerateFDA (Drugs)·D-0349-2023·2023-03-08
Microcrystalline Cellulose Ingredient Recalled Over Failed Impurity Specifications
DuPont Nutrition USA, Inc. is recalling certain batches of Avicel PH-101 microcrystalline cellulose because it failed quality testing for impurities and degradation. The ingredient showed out-of-specification conductivity levels.
Product
Avicel PH- 101 NF, Microcrystalline Cellulose, NF, Ph. Eur., Jp. Net Content/Gross Weight 50.0 KG / 54.5 KG bulk container, Manufactured by: DuPont Nutrition USA, Inc., 1301 Ogletown Road, Newark, DE 19711, USA. Headquarters: DuPont Nutrition Biosciences ApS, Langebrogade 1, Cope
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-0375-2023·2023-03-08
Buspirone Hydrochloride tablets recalled for manufacturing practice deviations
Accord Healthcare is recalling Buspirone Hydrochloride 7.5 mg tablets (23,784 bottles) distributed in the US, Puerto Rico, and Canada due to manufacturing practice deviations identified during FDA inspection.
Product
BUSPIRONE HYDROCHLORIDE — BUSPIRONE HYDROCHLORIDE (BUSPIRONE HYDROCHLORIDE)
Category
Drug
Distribution
1 state
ModerateFDA (Drugs)·D-0353-2023·2023-03-08
Prescription Levothyroxine Sodium Tablets Recalled Due to Sub-Potency
Alvogen is recalling 21,276 bottles of Levothyroxine Sodium Tablets (Lot HE02221, expiration 05/2023) distributed nationwide and in Puerto Rico due to sub-potency.
Product
LEVOTHYROXINE SODIUM — LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-0394-2023·2023-03-08
Glimepiride 2 mg tablets recalled for manufacturing practice deviations
Accord Healthcare recalls Glimepiride 2 mg tablets distributed in the US, Puerto Rico, and Canada due to Current Good Manufacturing Practice (CGMP) deviations identified during an FDA inspection. Approximately 992,622 bottles across multiple batches are affected.
Product
GLIMEPIRIDE — GLIMEPIRIDE (GLIMEPIRIDE)
Category
Drug
Distribution
1 state
ModerateFDA (Drugs)·D-0420-2023·2023-03-08
Pirfenidone Tablets Recalled Due to Manufacturing Compliance Deviations
Accord Healthcare is recalling Pirfenidone 801 mg tablets due to Current Good Manufacturing Practice deviations identified during an FDA inspection. Affected batches P2202519 and P2202513 were distributed in the United States, Puerto Rico, and Canada.
Product
PIRFENIDONE — PIRFENIDONE (PIRFENIDONE)
Category
Drug
Distribution
1 state
ModerateFDA (Drugs)·D-0431-2023·2023-03-08
Ropinirole Tablets Recalled Due to Manufacturing Quality Violations
Accord Healthcare is recalling Ropinirole 5mg tablets due to Current Good Manufacturing Practice (CGMP) deviations identified during an FDA inspection. The recall affects 5,112 bottles distributed in the United States, Puerto Rico, and Canada.
Product
ROPINIROLE — ROPINIROLE (ROPINIROLE)
Category
Drug
Distribution
1 state
ModerateFDA (Drugs)·D-0376-2023·2023-03-08
Accord Healthcare Recalls Buspirone Hydrochloride Due to Manufacturing Deviations
Accord Healthcare is recalling 24,408 bottles of Buspirone Hydrochloride tablets due to Current Good Manufacturing Practice deviations discovered during an FDA inspection.
Product
BUSPIRONE HYDROCHLORIDE — BUSPIRONE HYDROCHLORIDE (BUSPIRONE HYDROCHLORIDE)
Category
Drug
Distribution
1 state
ModerateFDA (Drugs)·D-0419-2023·2023-03-08
Pirfenidone tablets recalled due to manufacturing process deviations
Accord Healthcare recalls Pirfenidone tablets due to manufacturing practice deviations found during FDA inspection. The recall affects 2,614 cartons distributed in the US, Puerto Rico, and Canada.
Product
PIRFENIDONE — PIRFENIDONE (PIRFENIDONE)
Category
Drug
Distribution
1 state
ModerateFDA (Drugs)·D-0354-2023·2023-03-08
Gabapentin 600 mg Tablets Recalled Due to Dosage Strength Mix-Up
Sciegen Pharmaceuticals is recalling 4,392 bottles of Gabapentin 600 mg tablets after a pharmacist discovered some 800 mg tablets mixed into bottles.
Product
GABAPENTIN — GABAPENTIN (GABAPENTIN)
Category
Drug
Distribution
Distributed nationwide
LowFDA (Drugs)·D-0351-2023·2023-03-08
Avicel PH-200 pharmaceutical excipient recalled for failed conductivity specification
DuPont is recalling Avicel PH-200, a pharmaceutical excipient, because test results showed conductivity out of specification. No illnesses or injuries have been reported.
Product
Avicel PH-200 NF, Microcrystalline Cellulose, NF, Ph. Eur., Jp, Net Content/Gross Weight 20.0 KG / 21.1 KG bulk container, Manufactured by: DuPont Nutrition USA, Inc., 1301 Ogletown Road, Newark, DE 19711, USA. Headquarters: DuPont Nutrition Biosciences ApS, Langebrogade 1, Copen
Category
Drug
Distribution
Distributed nationwide
HighFDA (Drugs)·D-0334-2023·2023-03-01
Levothyroxine oral solution TIROSINT recalled nationwide for subpotency
IBSA Pharma voluntarily recalled TIROSINT levothyroxine sodium oral solution nationwide due to subpotency concerns. Affected lots are 220416 (Exp. 10/2023) and 221053 (Exp. 4/2024).
Product
TIROSINT — TIROSINT (LEVOTHYROXINE SODIUM)
Category
Drug
Distribution
Distributed nationwide
HighFDA (Drugs)·D-0338-2023·2023-03-01
Thyroid Medication TIROSINT Levothyroxine Sodium Nationwide Recall for Subpotency
IBSA Pharma Inc. is recalling TIROSINT (levothyroxine sodium) oral solution nationwide due to subpotency. Two lot numbers are affected: Lot #220407 (Exp. 10/2023) and Lot #220960 (Exp. 03/2024).
Product
TIROSINT — TIROSINT (LEVOTHYROXINE SODIUM)
Category
Drug
Distribution
Distributed nationwide
HighFDA (Drugs)·D-0346-2023·2023-03-01
FDA Recalls Sodium Chloride Injection Due to Incomplete Container Seals
B. Braun Medical's 0.9% Sodium Chloride Injection batches recalled due to risk of incomplete seals that could allow leakage, potentially compromising sterility. The recall affects 1,343,982 bags distributed nationwide.
Product
SODIUM CHLORIDE — SODIUM CHLORIDE (SODIUM CHLORIDE)
Category
Drug
Distribution
Distributed nationwide
HighFDA (Drugs)·D-0345-2023·2023-03-01
Prescription Levothyroxine Sodium Oral Solution Nationwide Recall Due to Subpotency
IBSA Pharma has recalled TIROSINT levothyroxine sodium oral solution nationwide due to subpotency. Affected lots 220418 and 220560 may contain insufficient active ingredient for proper thyroid hormone replacement therapy.
Product
TIROSINT — TIROSINT (LEVOTHYROXINE SODIUM)
Category
Drug
Distribution
Distributed nationwide
HighFDA (Drugs)·D-0332-2023·2023-03-01
Levothyroxine sodium oral solution recalled nationwide for subpotent dosing
IBSA Pharma is recalling TIROSINT levothyroxine sodium oral solution nationwide due to subpotent drug content. The recall affects lots 220413 and 220964.
Product
TIROSINT — TIROSINT (LEVOTHYROXINE SODIUM)
Category
Drug
Distribution
Distributed nationwide
HighFDA (Drugs)·D-0341-2023·2023-03-01
Thyroid Drug TIROSINT Recalled Due to Subpotent Formulation
IBSA Pharma Inc. recalls TIROSINT (levothyroxine sodium) oral solution nationwide due to subpotent formulation containing less active ingredient than labeled.
Product
TIROSINT — TIROSINT (LEVOTHYROXINE SODIUM)
Category
Drug
Distribution
Distributed nationwide
HighFDA (Drugs)·D-0336-2023·2023-03-01
Levothyroxine Oral Solution TIROSINT Recalled Due to Subpotency
IBSA PHARMA is recalling TIROSINT (levothyroxine sodium) oral solution due to subpotency in specific batches. The affected product may contain less active ingredient than labeled.
Product
TIROSINT — TIROSINT (LEVOTHYROXINE SODIUM)
Category
Drug
Distribution
Distributed nationwide
HighFDA (Drugs)·D-0348-2023·2023-03-01
Warfarin Sodium Tablets Recalled Due to Failed Impurity and Degradation Specifications
Rising Pharmaceuticals is recalling Warfarin Sodium Tablets USP 1 mg due to failed impurities and degradation specifications. Approximately 12,216 bottles may have been distributed nationwide.
Product
Warfarin Sodium Tablets, USP 1 mg, 100-count bottle, Rx Only, Distributed by: Rising Health, LLC, Saddle Brook, NJ 07663, NDC# 57237-119-01
Category
Drug
Distribution
Distributed nationwide
HighFDA (Drugs)·D-0335-2023·2023-03-01
Prescription Thyroid Medication TIROSINT Recalled for Subpotent Dosages Nationwide
IBSA Pharma is recalling certain lots of TIROSINT (levothyroxine sodium) oral solution nationwide because the product contains less active ingredient than labeled. Patients using affected lots may not receive adequate thyroid hormone replacement.
Product
TIROSINT — TIROSINT (LEVOTHYROXINE SODIUM)
Category
Drug
Distribution
Distributed nationwide
HighFDA (Drugs)·D-0339-2023·2023-03-01
Levothyroxine sodium oral solution recalled due to subpotency
IBSA Pharma Inc. has recalled TIROSINT levothyroxine sodium oral solution nationwide due to subpotency. Some doses may contain less active ingredient than labeled. Patients should contact their healthcare provider.
Product
TIROSINT — TIROSINT (LEVOTHYROXINE SODIUM)
Category
Drug
Distribution
Distributed nationwide
HighFDA (Drugs)·D-0331-2023·2023-03-01
Prescription drug TIROSINT levothyroxine recalled for subpotent formulation
IBSA Pharma has recalled two lots of TIROSINT levothyroxine sodium oral solution nationwide because they contain less active ingredient than labeled. The affected lots are 220409 (expiring 10/2023) and 220956 (expiring 03/2024).
Product
TIROSINT — TIROSINT (LEVOTHYROXINE SODIUM)
Category
Drug
Distribution
Distributed nationwide

How to read this listing

Filters

2976–3000 of 17762